AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.
News|Articles|April 30, 2026
Recap: Day 3 of Asembia AXS26
These discussions focused on gaps in artificial intelligence, community-based advanced therapy, and demands of federal drug price negotiations.
Advertisement
Advertisement
The Asembia AXS26 Summit sessions further emphasized the critical need for operational readiness across the specialty pharmacy ecosystem. As the industry grapples with the transition from theoretical innovation to large-scale implementation, these discussions focused on bridging the gaps in artificial intelligence (AI) production, community-based advanced therapy delivery, and the rigorous demands of federal drug price negotiations.
Related to this article
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
Sara Hover, RPh, FAARM, explains how these products are putting pharmacists at the center of safety and evidence evaluations one patient at a time.
In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
Advertisement
Advertisement